SMARCB1 and ovarian small cell carcinoma: Interestingly, SMARCB1-mutant rhabdoid tumors and SMARCA4-mutant small cell carcinoma of the ovary have an immune active microenvironment and are responsive to immune-checkpoint inhibition [18,48,49].